Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer

Events, News, Presentations, Press Releases

Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer – Results from the STRO-002 (luvelta) Phase 1 dose-expansion study demonstrate that FolRα-selected...

Sutro Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference

Events, News, Presentations, Press Releases

Sutro Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference SOUTH SAN FRANCISCO, Calif., January 4, 2023 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format...

Sutro Biopharma to Provide Data Update on STRO-002 and Plans for Registrational Path Forward in Advanced Ovarian Cancer

Events, News, Presentations, Press Releases

Sutro Biopharma to Provide Data Update on STRO-002 and Plans for Registrational Path Forward in Advanced Ovarian Cancer – Conference call and webcast to be held on Monday, January 9, 2023 at 1:30 pm PT, or 4:30 pm ET – SOUTH SAN FRANCISCO, Calif., December...

Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract

News, Press Releases

Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract – New Agreement Provides Vaxcyte Access to Expanded Rights to Develop and Manufacture Cell-Free Extract, a Key Component of...

Sutro Biopharma Announces Presentation of STRO-002 Data from the Compassionate Use Program in Pediatric Patients with Relapsed/Refractory CBF/GLIS AML at ASH 2022

Events, News, Presentations, Press Releases

Sutro Biopharma Announces Presentation of STRO-002 Data from the Compassionate Use Program in Pediatric Patients with Relapsed/Refractory CBF/GLIS AML at ASH 2022 – A total of 17 pediatric patients were treated with STRO-002 on a compassionate use basis; eight...

Sutro Biopharma to Participate in Upcoming Investor Conferences

Events, News, Presentations, Press Releases

Sutro Biopharma to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., November 23, 2022 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug...